RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
04 nov. 2020 10h30 HE
|
RedHill Biopharma Ltd.
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
14 oct. 2020 11h00 HE
|
RedHill Biopharma Ltd.
RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks--Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S....
RedHill Biopharma to Host Second Quarter 2015 Financial Results Conference Call on July 29, 2015
23 juil. 2015 06h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, July 23, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Prices Public Offering of Its American Depository Shares
16 juil. 2015 19h55 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, July 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101
15 juil. 2015 07h00 HE
|
RedHill Biopharma Ltd.
RedHill has extended the term of the exclusive option agreement for the oncology drug candidate RP101 for an additional year
RP101 is a proprietary, first-in-class, orally-administered,...
RedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26, 2015
19 févr. 2015 08h00 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 19, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
13 févr. 2015 10h18 HE
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG
30 juin 2014 06h00 HE
|
RedHill Biopharma Ltd.
RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...
RedHill Biopharma Reports Results for the First Quarter of 2014
30 avr. 2014 11h00 HE
|
RedHill Biopharma Ltd.
Key financial highlights include:
A first profitable quarter, with net income of $3.4 million, primarily attributed to the $7 million upfront payment received from Salix Pharmaceuticals as part...
RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3/2014
30 avr. 2014 07h00 HE
|
RedHill Biopharma Ltd.
RedHill received positive results from a comparative bioavailability clinical trial which included 20 healthy volunteers
In light of the positive results, and subject to regulatory...